Premium
Effects of SU‐13437 on serum lipids in hyperlipoproteinemic patients
Author(s) -
Weiss Peter,
Dujovne Carlos A.,
Margolis Simeon,
Lasagna Louis,
Bianchine Joseph R.
Publication year - 1970
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt197011190
Subject(s) - transaminase , placebo , crossover study , medicine , gastroenterology , blood lipids , serum cholesterol , endocrinology , cholesterol , chemistry , pharmacology , biochemistry , pathology , enzyme , alternative medicine
The ability of a tetralin phenoxy isobutyrate, SU‐13437, to lower serum lipids was compared with that of a matching placebo in a double‐blind crossover study. Treatment with SU‐13437 for 4 weeks lowered serum cholesterol by 23 per cent in hypercholesterolemic patients, and it lowered serum triglycerides by 68 per cent in hypertriglyceridemic patients. None of the patients failed to respond to treatment. Gastrointestinal upset was seen in 2 of the 29 patients, and one patient had transient elevation of serum glutamic oxaloacetic transaminase.